Samuel Muench, MD
Gastroenterology · Bethesda, MDNPI 1164871562
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,013 of the $34,127 with a category attached, or 61.6%. 35 manufacturers reported payments, led by Madrigal Pharmaceuticals at 40.4% of the total. 2025 is the largest year on record at $25,772, more than ten times the $230 reported in 2021. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $99.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$14K
- Exact Sciences$8K
- Johnson & Johnson$3K
- Bristol Myers Squibb$1K
- AbbVie$1K
- Pfizer$724
- plus $6K from 29 others
What the payments were for
- Consulting fees$21,01362%
- Travel & lodging$1,0743%
- Food & beverage$12,03735%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 28 | $13,804 |
| Exact Sciences | 17 | $8,143 |
| Johnson & Johnson | 41 | $2,809 |
| Bristol Myers Squibb | 31 | $1,258 |
| AbbVie | 49 | $1,249 |
| Pfizer | 27 | $724 |
| Regeneron Healthcare Solutions, Inc. | 18 | $615 |
| Sanofi | 12 | $598 |
| Boston Scientific | 5 | $444 |
| Janssen Scientific Affairs, LLC | 5 | $438 |
| Ipsen Biopharmaceuticals, Inc | 7 | $409 |
| Lilly USA, LLC | 9 | $357 |
| Phathom Pharmaceuticals, Inc. | 19 | $354 |
| Ardelyx, Inc. | 8 | $300 |
| Gilead | 3 | $289 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $273 |
| E.r. Squibb & Sons, L.L.C. | 2 | $264 |
| Intercept Pharmaceuticals, Inc. | 7 | $258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $244 |
| Celltrion USA Inc. | 8 | $233 |
| Steris Corporation | 1 | $217 |
| Olympus America Inc. | 1 | $149 |
| Aimmune Therapeutics, Inc. | 4 | $134 |
| Conmed Corporation | 1 | $98 |
| Daiichi Sankyo Inc. | 3 | $77 |
| Ironwood Pharmaceuticals, Inc | 4 | $76 |
| Ferring Pharmaceuticals Inc. | 3 | $75 |
| Enterra Medical, Inc. | 2 | $55 |
| Lucid Diagnostics Inc. | 2 | $43 |
| Novo Nordisk | 2 | $39 |
| Braintree Laboratories, Inc. | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $25 |
| Evoke Pharma, Inc. | 1 | $18 |
| Orphalan Inc | 1 | $17 |
| Sandoz | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$13,103
- Cologuard Collection Kit$7,563
- Tremfya$2,169
- The Cologuard Plus Collection Kit$1,700
- ZEPOSIA$846
- DUPIXENT$498
- IQIRVO$265
- Rinvoq$237
- TRUFREEZE$217
- EXALT Model D$161
- Endocuff Vision$149
- DISPOSABLE TRIPLE LUMEN SPHINCTEROTOME$149
- Single Use Electrosurgical Knife KD-655$149
- Single Use Electrosurgical Hemostatic Forceps$149
- VELSIPITY$142
- IBSRELA$134
- VEGZELMA$122
- OMVOH$116
- GENERAL ENDOCHOICE$110
- OCALIVA$108
How this compares
$34,127 in reported general payments places this provider in the 90th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 11 | $97,471 |
| MounjaroTirzepatide | 25 | $28,771 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 55 | $3,169 |
| Pantoprazole Sodium | 42 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,249 | $97,47111 claims |
| Lilly USA, LLCMounjaro | $357 | $28,77125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Bethesda
- Maria SjogrenBethesda$75K
- John BassettBethesda$61K
- Reezwana ChowdhuryBethesda$40K
- Eric PollackBethesda$15K
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Zachary BormanChevy Chase$520K
- Mouen KhashabBaltimore$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.